La chaîne d'options affiche les données clés des options sur actions de Seelos Therapeutics Inc COM PAR NEW $0.001 à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Seelos Therapeutics Inc COM PAR NEW $0.001..

Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) Stock, Chaîne d'Options

Seelos Therapeutics

Seelos Therapeutics Inc COM PAR NEW $0.001

Seele-N

SEELOS THERAPEUTICS INC by Seelos Therapeutics, Inc.

Seelos Therapeutics Inc

Government

Macro Economic Events

Politics

Economics

General

'Trump's Plan To Impose 25% Tariffs On Canadian And Mexican Imports Does Not Exempt Crude Oil - Sources'

<a href="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/" title="https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/">https://www.reuters.com/world/middle-east/israel-security-cabinet-approves-ceasefire-deal-with-lebanon-tv-2024-11-26/</a>

News

iShares MSCI Israel Capped Investable Market Index Fund

'Israel Security Cabinet Approves Ceasefire Deal With Lebanon - TV' - Reuters

Whales with a lot of money to spend have taken a noticeably bullish stance on Intuitive Surgical.
Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 9% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $77,900 and 9, calls, for a total amount of $448,950.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $560.0 for Intuitive Surgical, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Intuitive Surgical options trades today is 157.75 with a total volume of 182.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuitive Surgical's big money trades within a strike price range of $240.0 to $560.0 over the last 30 days.
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644997_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.3</td>
<td>$19.6</td>
<td>$19.7</td>
<td>$550.00</td>
<td>$78.8K</td>
<td align="right">575</td>
<td align="right">54</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$65.0</td>
<td>$60.7</td>
<td>$65.0</td>
<td>$520.00</td>
<td>$65.0K</td>
<td align="right">173</td>
<td align="right">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$64.9</td>
<td>$61.4</td>
<td>$63.0</td>
<td>$520.00</td>
<td>$63.0K</td>
<td align="right">173</td>
<td align="right">20</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$305.0</td>
<td>$300.7</td>
<td>$302.7</td>
<td>$240.00</td>
<td>$60.5K</td>
<td align="right">52</td>
<td align="right">2</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.8</td>
<td>$27.6</td>
<td>$28.8</td>
<td>$560.00</td>
<td>$57.6K</td>
<td align="right">140</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Intuitive Surgical</h3>
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a trading volume of 478,667, the price of ISRG is up by 0.66%, reaching $540.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

ISRG

Unpacking the Latest Options Trading Trends in Intuitive Surgical

Whales with a lot of money to spend have taken a noticeably bullish stance on Microchip Technology.
Looking at options history for Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $647,449 and 3, calls, for a total amount of $215,668.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $47.5 to $87.5 for Microchip Technology during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Microchip Technology stands at 373.38, with a total volume reaching 5,381.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Microchip Technology, situated within the strike price corridor from $47.5 to $87.5, throughout the last 30 days.
<h3>Microchip Technology Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644993_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$70.00</td>
<td>$430.3K</td>
<td>489</td>
<td>1.4K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.9</td>
<td>$70.00</td>
<td>$98.0K</td>
<td>584</td>
<td>212</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.3</td>
<td>$2.2</td>
<td>$2.18</td>
<td>$77.50</td>
<td>$76.7K</td>
<td>140</td>
<td>751</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.05</td>
<td>$2.0</td>
<td>$2.05</td>
<td>$67.50</td>
<td>$49.6K</td>
<td>1.1K</td>
<td>435</td>
</tr>
<tr>
<td>MCHP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$70.00</td>
<td>$41.0K</td>
<td>298</td>
<td>314</td>
</tr>
</tbody>
</table>

<h3>About Microchip Technology</h3>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
In light of the recent options history for Microchip Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Microchip Technology</h3>
<ul>
<li>Trading volume stands at 3,162,874, with MCHP's price down by -1.88%, positioned at $68.54.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 65 days.</li>
</ul>
<h3>Professional Analyst Ratings for Microchip Technology</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $88.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on Microchip Technology, maintaining a target price of $90. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Microchip Technology, targeting a price of $82. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Microchip Technology with a target price of $90. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Microchip Technology with a target price of $85. 
&#x2A; An analyst from Evercore ISI Group downgraded its action to Outperform with a price target of $95. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MCHP

Microchip Technology Unusual Options Activity

<a href="https://news.sky.com/story/apollo-in-talks-to-finance-new-york-sun-owners-550m-telegraph-bid-13261183#:~:text=The%20%24733bn%20alternative%20investments,newspaper%2C%20Sky%20News%20can%20reveal.">https://news.sky.com/story/apollo-in-talks-to-finance-new-york-sun-owners-550m-telegraph-bid-13261183#:~:text=The%20%24733bn%20alternative%20investments,newspaper%2C%20Sky%20News%20can%20reveal.</a>
&nbsp;
One of the world's largest investment groups is in talks to help finance a £550m takeover of The Daily Telegraph by the owner of The New York Sun.
Sky News has learnt that Apollo Global Management, which oversees assets worth $733bn, has been holding initial talks with Dovid Efune and his advisers in recent days about lending part of the money required for the deal.
Banking sources said on Tuesday that the discussions were preliminary in nature and might not lead to an agreement.
Other debt providers are also in talks with Mr Efune, the sources added.
The development has emerged just three days before an exclusivity period for the US-based businessman expires, although insiders say it is almost certain to be extended.
Apollo ranks among the world's biggest financial institutions and is a major player in both private equity and private credit around the globe.
In the last fortnight, a string of media reports have cast doubt on Mr Efune's ability to complete the deal, with potential lenders including Oaktree Capital Management and Hudson Bay Capital said to have withdrawn from the process.

'Apollo In Talks To Finance New York Sun-Owner's £550m Telegraph Bid; The $733B Alternative Investments Behemoth Is In Preliminary Discussions To Help Fund Dovid Efune's Takeover Of The Right-leaning Newspaper' - Sky News

Deep-pocketed investors have adopted a bullish approach towards Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HOOD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Robinhood Markets. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $329,380, and 32 are calls, amounting to $2,224,324.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $50.0 for Robinhood Markets during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Robinhood Markets's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Robinhood Markets's substantial trades, within a strike price spectrum from $20.0 to $50.0 over the preceding 30 days.
<h3>Robinhood Markets Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732644987_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$50.00</td>
<td>$598.8K</td>
<td>2.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.0</td>
<td>$8.9</td>
<td>$9.0</td>
<td>$37.00</td>
<td>$270.0K</td>
<td>1.2K</td>
<td>300</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$18.25</td>
<td>$18.05</td>
<td>$18.15</td>
<td>$20.00</td>
<td>$232.3K</td>
<td>118</td>
<td>130</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.75</td>
<td>$37.00</td>
<td>$117.2K</td>
<td>2.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.95</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$50.00</td>
<td>$109.0K</td>
<td>4.7K</td>
<td>137</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
After a thorough review of the options trading surrounding Robinhood Markets, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Robinhood Markets's Current Market Status</h3>
<ul>
<li>With a trading volume of 8,734,368, the price of HOOD is down by -1.95%, reaching $37.11.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Expert Opinions on Robinhood Markets</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $33.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on Robinhood Markets, maintaining a target price of $25. 
&#x2A; An analyst from Needham upgraded its action to Buy with a price target of $40. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Neutral rating for Robinhood Markets, targeting a price of $22. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Robinhood Markets, maintaining a target price of $26. 
&#x2A; An analyst from Morgan Stanley has elevated its stance to Overweight, setting a new price target at $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Robinhood Markets with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

HOOD

Spotlight on Robinhood Markets: Analyzing the Surge in Options Activity

Retirement brings exciting possibilities but also requires careful financial planning to ensure long-term stability. In a <a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-highlights-from-create-the-li">recent Women &amp; Money podcast episode</a>, financial expert <a href="https://www.benzinga.com/personal-finance/24/11/42094171/new-car-or-old-reliable-suze-ormans-surprising-advice-on-listeners-20-year-old-car">Suze Orman</a> responded to a listener named Linda, who asked whether retirees should keep one year or five years' cash in an emergency fund. Orman's advice offered insights into navigating market fluctuations during retirement.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
</ul>
According to Orman, most retirees depend on their retirement accounts, such as Roth or traditional IRAs, to fund their monthly living expenses. These accounts often hold investments in stocks, bonds or mutual funds. While these assets grow over time, their value fluctuates with the market.&nbsp;
Orman says the problem arises when retirees need to withdraw money from their accounts during a market crash. Selling stocks or bonds during a market downturn can cut into retirement savings, potentially jeopardizing future <a href="https://www.benzinga.com/personal-finance/24/09/40764819/think-youre-financially-secure-heres-how-much-people-say-it-takes-to-feel-secure-and-what-you-re">financial security</a>.&nbsp;
To address this risk, Orman recommends that retirees keep a cash reserve with three to five years of living expenses. "If you really wanna be on the safe side, it's five years," she said.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
This cash reserve acts as a safety net, allowing retirees to withdraw the funds they need rather than selling and withdrawing from their investment accounts during a market slump.&nbsp;
Orman explains that keeping three to five years&#8217; worth of expenses is important because that's how long it often takes the markets to recover from significant downturns. Having enough cash for that time minimizes the need to sell at a loss, ensuring retirees can leave their investments alone long enough to regain their value.&nbsp;
It usually takes the markets longer to recover during a recession. According to Invesco, the average decline during the "more mild" recessions in the '80s and '90s was around 20% and the stock market recovered from these within one to two years.&nbsp;
The more extreme recessions, like the 2008 financial crisis, extend that recovery time. 5 paisa, an online investing and trading platform, states it wasn't until 2013 that the market recovered to its precrisis levels.&nbsp;
Trending: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
If you're <a href="https://www.benzinga.com/personal-finance/24/10/41602038/new-report-reveals-62-of-u-s-retirees-leave-the-workforce-sooner-than-expected-and-people-are-no">nearing retirement</a> and don't yet have a sufficient cash reserve, Orman recommends creating one strategically. She says to evaluate your investments and consider selling stocks or assets that aren't performing well or that you don't believe will yield strong future returns. Another option she proposes is taking small amounts from well-performing investments to gradually build your reserve.&nbsp;
For those needing access to their money immediately, Ameriprise Financial recommends keeping cash reserves in a high-yield savings or deposit account, cash management account or sweep account. Alternatively, if you can wait one to three months to access those cash reserves – for instance, if you have a couple months of cash to cover expenses in your checking account – they say to consider keeping the funds in money market funds or investment certificates.&nbsp;
For retirees like Linda, maintaining three to five years of cash reserves is a proactive step toward financial security. This strategy protects against the unpredictability of market downturns and allows investments to recover without being prematurely liquidated.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Suze Orman Says To Have At Least 3 To 5 Years Of Cash Available When Retired: Here's Why

On Tuesday, Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) posted&nbsp;the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42184816/embecta-corp-reports-fiscal-2024-fourth-quarter-and-full-year-financial-results-provides-initial-f" rel="noreferrer noopener">consensus of $277 million</a>.
&#8220;We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics&#8230;Additionally, the recent launch of our small-pack GLP-1 needles in Germany has gone well, and we are evaluating expanding into other markets,&#8221; said Devdatt (Dev) Kurdikar, Chief Executive Officer of Embecta.
The Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech <a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
&#8220;We intend to concentrate our resources on our core business and to prioritize our free cash flow towards paying down debt, which we expect will give us the financial flexibility needed for future investments,&#8221; Kurdikar said.
Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of its patch pump program.
In total, Embecta expects between $35 million and $45 million in pre-tax charges in 2025 related to its restructuring plan. It anticipates completing the restructuring in the first half of 2025. Embecta projects annual cost savings of $60 million to $65 million from this restructuring.
Given the organizational restructuring plan, the company has postponed its Analyst &amp; Investor Day to Spring 2025.
Guidance: Embecta says that for the fiscal year 2025, excluding the Patch Pump program, revenues are expected to be $1.093 billion—$1.11 billion compared to a consensus of $1.12 billion, with an adjusted EPS of $2.70—$2.90 versus the consensus of $2.27.
Price Action: EMBC stock is up 33.5% at $19.23 at last check Tuesday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42195803/why-is-exact-sciences-stock-trading-higher-on-monday" target="_blank" rel="noreferrer noopener">Why Is Exact Sciences Stock Trading Higher On Monday?</a></li>
</ul>

Earnings

Equities

Guidance

Health Care

Movers

Trading Ideas

EMBC

Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps

<a href="https://ppubs.uspto.gov/pubwebapp/external.html?q=(12152936).pn">https://ppubs.uspto.gov/pubwebapp/external.html?q=(12152936).pn</a>
<figure class="image"><img src="https://pbs.twimg.com/media/GdU1yQkWQAAh4uq?format=jpg&amp;name=900x900" alt="Image" /></figure>

Quantum-Si Granted US Patent #12152936 For "INTEGRATED CIRCUIT WITH SEQUENTIALLY-COUPLED CHARGE STORAGE AND ASSOCIATED TECHNIQUES"

Anthony Scaramucci opined on President-elect Donald Trump&#8216;s successful election bid, analyzed the results and their implications <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">for crypto policy</a>.
What Happened: In a recent <a href="https://www.youtube.com/watch?v=C9Yh-2jNTdI">episode</a> of The Scoop podcast with Frank Chaparro, the former White House Communications Director pointed to Vice President Kamala Harris's loss as a consequence of economic concerns and unreliable polling, calling Trump's narrow win "the greatest political comeback in U.S. history."
On the topic of crypto, Scaramucci asserted that the Democrats&#8217; anti-crypto stance hurt their political standing, stating, "You won no electoral votes, you won no States, you won no seats in the senate or the house being anti-crypto."
He suggested that <a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">regulatory roadblocks</a> under the Democrats suppressed the crypto market, adding, "Where you are now in price is where we should have been three years ago."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42024635/scaramucci-trumps-crypto-support-could-push-bitcoin-to-150k">Scaramucci: Trump&#8217;s Crypto Support Could Push Bitcoin To $150K</a>
Why It Matters: Scaramucci predicts the incoming Trump administration will prioritize loyalty over expertise, creating a potentially disruptive cabinet. 
He highlighted concerns over controversial appointments, <a href="https://www.benzinga.com/politics/24/11/42170037/elon-musk-said-matt-gaetz-would-be-hammer-of-justice-as-attorney-general-former-congressman-now-unemployed-sells-cameos-for-500">including Matt Gaetz</a>, but expressed optimism about crypto-related appointments like Brian Brooks as <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">a possible SEC chair</a>.
The crypto <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42122348/trumps-planned-crypto-council-may-oversee-bitcoin-reserve-report">surge following Trump's re-election</a>, Scaramucci noted, represents the market correcting itself after years of regulatory suppression. 
However, he also warned of a potential &#8220;rug pull&#8221; scenario, advising caution despite his overall optimism.
Scaramucci briefly commented on <a href="https://www.benzinga.com/startups/24/11/42069236/trump-tasked-elon-musk-to-oversee-government-efficiency-heres-how-musk-has-streamlined-costs-at-his-own-companies">Trump's relationship</a> with Elon Musk, describing it as "unsustainable" due to Trump's resistance to anyone becoming "richer or more famous" than him.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42154487/robert-kiyosaki-trump-will-make-america-richer-again-by-being-the-first-bitcoin-president">Robert Kiyosaki: &#8216;Trump Will Make America Richer Again By Being The First Bitcoin President&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Anthony Scaramucci: Trump Win Is 'The Greatest Political Comeback In US History,' Crypto Surge Following It Was 3 Years Overdue

<a href="https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/" title="https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/">https://www.cbsnews.com/news/us-air-force-drone-sightings-uk-military-bases-unexplained-ongoing/</a>

'U.S. Air Force Says Unexplained Drone Sightings Near U.K. Military Bases Ongoing' - CBS

Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's <a href="https://www.benzinga.com/general/health-care/24/11/42087908/mutated-bird-flu-case-in-california-puts-humans-at-increased-risk-so-which-companies-are-developing-vaccines">department of public health.&nbsp;</a>
The Details: The virus was found during testing of a batch of whole raw milk from Raw Farm in Fresno county. The company has issued a voluntary recall of the batch, which has a &#8220;best by date&#8221; of Nov. 27. 
"Out of an abundance of caution, and due to the ongoing spread of bird flu in dairy cows, poultry, and sporadic human cases, consumers should not consume any of the affected raw milk," the California Department of Public Health said in <a href="https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-039.aspx">a Sunday statement.&nbsp;</a>
Read More: <a href="https://www.benzinga.com/24/11/42194570/starbucks-employee-systems-down-after-software-provider-suffers-ransomware-attack">Starbucks&#8217; Employee Systems Down After Software Provider Suffers Ransomware Attack</a>
California reported 29 confirmed human cases of bird flu since early October, with 28 of the cases resulting from direct contact with infected dairy cows. No person-to-person spread of bird flu has been detected in California or the U.S., according to the state's public health department.&nbsp;
Vaccine Efforts: As concern about the possible spread of bird flu grows, the U.S. government is increasing its efforts to develop a stockpile of vaccines for the disease.&nbsp;
Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) received a $176 million government contract in July to advance development of its bird flu vaccine, leveraging the same mRNA technology used in the company's COVID-19 vaccine.&nbsp;&nbsp;
In October, the Department of Health and Human Services granted GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Australian firm CSL Limited $72 million to <a href="https://www.benzinga.com/general/biotech/24/10/41188886/gsk-sanofi-and-csl-secure-us-government-fund-to-boost-bird-flu-vaccine-production-report">more than double</a> the U.S. supply of bird flu vaccines.&nbsp;
According to the CDC, 55 total cases have been reported in the 2024 bird flu outbreak in the U.S. The CDC said that it is monitoring <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">the bird flu situation </a>carefully and working with states to monitor people with animal exposures, though the current public health risk is low.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Pexels

Biotech

MRNA

Bird Flu Found In Raw Milk Leads To Recall In California

Wolfe Research analyst Timna Tanners downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Outperform to Peer Perform.

Downgrades

Analyst Ratings

Wolfe Research Downgrades Summit Materials to Peer Perform

Wolfe Research analyst Scott Group initiates coverage on Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Aurora Innovation with Peer Perform Rating

WIIM

ICAD

iCAD shares are trading higher after the company announced it will present its next-generation AI solutions and a second-read AI partnership with Cascaid Health at the RSNA 2024 Annual Meeting.

Wolfe Research analyst Nigel Coe initiates coverage on Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Outperform rating and announces Price Target of $125.

Price Target

Wolfe Research Initiates Coverage On Pentair with Outperform Rating, Announces Price Target of $125

VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Tuesday</a>.
The company reported a third-quarter loss per share of 23 cents, which <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42191746/vinfast-reports-unaudited-third-quarter-2024-financial-results" rel="noreferrer noopener">beat the analyst consensus estimate for a loss of 28 cents</a>. Quarterly sales of $511.6 million (+49.3%) beat the street view of $477.25 million.
The company delivered delivering 21,912 vehicles, representing a 115% year-over-year increase.
&#8220;We expect to finish 2024 on a strong note and meet our 80,000-vehicle delivery target, as the momentum in Q3 has continued into Q4,&#8221; said Madam&nbsp;Thuy Le, Chairwoman of VinFast.
Notably,&nbsp;B2C deliveries experienced a considerable quarterly increase of 163%, highlighting strong market demand for VinFast&#8217;s EVs.
The gross margin in the third quarter of 2024 was negative 24.0%, compared to the negative 27.0% margin in the same quarter of the previous year.
Also Read:<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs" rel="noreferrer noopener"> Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs</a>
Recently, VinFast said its Founder and Chief Executive Officer, Pham Nhat Vuong, and his associated companies intend to provide up $2.1 billion in free grants to the company and its subsidiaries through the end of 2026.
In addition, Vingroup Joint Stock Company intends for it and its subsidiaries to provide VinFast&#8217;s subsidiaries incorporated in&nbsp;Vietnam&nbsp;with up to&nbsp;$1.5 billion in loans through the end of 2026.
&#8220;Our overall liquidity position has been enhanced by the recently announced loans from Vingroup and grants from our Founder, whereby we expect to receive a potential of&nbsp;$3.5 billion&nbsp;injection by the end of 2026,&#8221; said Lan Anh Nguyen, Chief Financial Officer of VinFast.
VinFast aims to meet its annual delivery target of 80,000 vehicles, driven by strong momentum in Vietnam and North America.
The company is focused on cost optimization and improving profitability while expanding its global presence.
Price Action: VFS shares are trading higher by 1.15% to $3.975 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42187787/intel-to-receive-nearly-8-billion-in-federal-funding-under-chips-act-for-us-expansion" target="_blank" rel="noreferrer noopener">Intel To Receive Nearly $8 Billion In Federal Funding Under CHIPS Act for US Expansion</a></li>
</ul>
Image via Shutterstock.

VinFast Powers Ahead: Q3 Sales Surge 49%, Vehicle Deliveries Double & More

In the latest quarter, 6 analysts provided ratings for California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $66.83, a high estimate of $74.00, and a low estimate of $57.00. This current average has increased by 9.56% from the previous average price target of $61.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732644148_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of California Resources among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Deckelbaum</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Michael Schwartz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to California Resources. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of California Resources compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into California Resources's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on California Resources analyst ratings.</a>
<h2>Delving into California Resources's Background</h2>
California Resources Corp is an independent oil and natural gas exploration and production company operating properties exclusively within California. It provides affordable and reliable energy in a safe and responsible manner, to support and enhance the quality of life of Californians and the local communities in which the company operates. It has some of the lowest carbon intensity production in the United States and is focused on maximizing the value of its land, mineral, and technical resources for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects.
<h3>Financial Insights: California Resources</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: California Resources's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 51.38%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: California Resources's net margin excels beyond industry benchmarks, reaching 34.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): California Resources's ROE excels beyond industry benchmarks, reaching 12.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): California Resources's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: California Resources's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.35.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For California Resources

<a href="https://www.globenewswire.com/Tracker?data=TwjwrnlfW8Qen5u-zdYndKlr5vcGHoIuWTd0bH48Nh3tPUf8i9YA2cWS9NOEhDzB7CEJy_s4AP5ay5ShFgjuBQ==">iCAD, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5.
Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical research presentations, and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions.

iCAD Presents Next-Generation AI Solutions And A Second-Read AI Partnership With Cascaid Health At RSNA 2024

Ratings for Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Charter Communications, revealing an average target of $378.33, a high estimate of $450.00, and a low estimate of $300.00. Observing a 4.19% increase, the current average has risen from the previous average price target of $363.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1732644127_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Charter Communications. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kohulan Paramaguru</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Bryan Kraft</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$365.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$390.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Sebastiano Petti</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Jessica Ehrlich</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Peter Supino</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$345.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$350.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Charter Communications. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Charter Communications compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Charter Communications's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Charter Communications's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CHTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Charter Communications analyst ratings.</a>
<h2>Discovering Charter Communications: A Closer Look</h2>
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 58 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
<h3>Charter Communications: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Charter Communications's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.55%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Charter Communications's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 9.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Charter Communications's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.86%, the company showcases effective utilization of assets.
Debt Management: Charter Communications's debt-to-equity ratio stands notably higher than the industry average, reaching 6.83. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHTR

Unveiling 12 Analyst Insights On Charter Communications

Seelos Therapeutics files to sell 1.95M shares of common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) just reported results for the second quarter of 2024.<ul><li>Seelos Therapeutics reported earnings per share of 12 cents.</li><li>The company reported revenue of $376,000.</li><li>This was 25.33% better than the analyst estimate for revenue of $300,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/seel-stock-earnings-seelos-therapeutics-for-q2-of-2024/">SEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report

Seelos Therapeutics files to sell common stock, warrants, no amount given

Seelos Therapeutics, Heart Test Laboratories, and XChange TEC are the 3 Penny Stocks to watch on September 25, 2024, based on&nbsp;TipRanks' Penny ...

3 Penny Stocks to Watch Now, 9/25/24

Seelos Therapeutics to execute 1-for-16 reverse stock split

Seelos Therapeutics ( ($SEEL) ) just unveiled an update. Seelos Therapeutics, Inc. has announced a 1-for-16 reverse stock split scheduled to take e...

Seelos Therapeutics Announces Reverse Stock Split and Adjustments

Seelos gets Nasdaq delisting notice

RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up

ASND

ATAI

ATNF

AYRO

BIDU

BILI

BNTX

BTBT

CARA

CATO

CMND

CMPS

COTY

CSIQ

CTXR

CYBN

DRUG

ENVB

ESTC

FORD

FUTU

GGAL

GHRS

HSCS

IMMR

INTU

IXHL

JKHY

KEYS

MBRX

MMAT

MNMD

NNDM

NNOX

NTES

NVAX

PANW

PCVX

PTON

ROST

SEEL

SNOW

SNPS

SPRC

SXTP

URBN

VIPS

WDAY

WKHS

WOLF

XPEV

Press Releases

Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations

Stock Split

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split

Offerings

Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD

Biotech Soars On Material Transfer Agreement

"Nasdaq Stocks Set for Explosive Growth: BNZI, SEEL, PRSO, MSS, HSCS Revamp for Big Potential"

Seelos Therapeutics Announces 1-for-16 Reverse Stock Split

Seelos Announces Postponement of its Annual Meeting of Stockholders

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Comments

Seelos Therapeutics Inc COM PAR NEW $0.001

Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL